Christina Lake Cannabis Valuation

Is CLC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CLC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLC?

Key metric: As CLC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CLC. This is calculated by dividing CLC's market cap by their current revenue.
What is CLC's PS Ratio?
PS Ratio	0.4x
Sales	CA$12.49m
Market Cap	CA$4.59m

CLC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	11.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CLC's PS Ratio compare to its peers?

The above table shows the PS ratio for CLC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.4x
CANB CanadaBis Capital	0.4x	n/a	CA$6.9m
AYUR Ayurcann Holdings	0.3x	n/a	CA$6.8m
BBM Blueberries Medical	20.8x	n/a	CA$6.0m
AVNT Avant Brands	0.2x	n/a	CA$6.2m
CLC Christina Lake Cannabis	0.4x	n/a	CA$4.6m

Price-To-Sales vs Peers: CLC is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does CLC's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 Companies	Price / Sales	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.2x	2.6%	US$79.02m
TIUM.U Cansortium	0.2x	n/a	US$27.19m
RWB Red White & Bloom Brands	0.2x	n/a	US$16.83m
ACRG.A.U Acreage Holdings	0.1x	n/a	US$19.60m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CLC is good value based on its Price-To-Sales Ratio (0.4x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is CLC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CLC's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$127.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.59

8.0%

-43.4%

Medexus Pharmaceuticals

CA$53.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.13

4.9%

38.3%

Verano Holdings

CA$829.5m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.14

-15.4%

-63.8%